BIIB
Biogen Inc.Healthcare · $33.5B market cap
Verdict
Share price
$219.88
close of Oct 3, 2026
Fair value
$130.99
Sticker Price
Payback Price
$52.40
buy price
BIIB is Overpriced: at $219.88 it trades 68% above its fair value of $130.99. Its buy price (Payback Price) is $52.40, 76% below today's price. Business quality is mixed: 2 of 5 key numbers clear the 10% bar.
How we valued it
Free Cash Flow. Sales grew -1% a year over the last 3 years, below the 15% we look for in a fast grower, so we value it on its free cash flow instead of an earnings forecast.
Business quality
2 of 5 clear the 10% bar. What are the Big Five?
Follow BIIB
Get notified when it reaches its buy price of $52.40. Free.
Create a free accountSuperinvestors
4 of the investors we track hold BIIB. In Q2 2026, 2 trimmed. Who we track
Samantha McLemore
Patient Capital Management · as of Q2 2026
$61.3M
283,697 shares
Sarah Ketterer
Causeway Capital Management · as of Q2 2026
$60.1M
278,283 shares
Samantha McLemore
Patient Capital Management · as of Q2 2026
$40.9M
189,400 shares
Hillman Capital Management
Hillman Capital Management · as of Q2 2026
$5.2M
23,993 shares
Moves in Q2 2026
Trimmed: Samantha McLemore, Hillman Capital Management
Insider activity
Since Aug 3, 2026: no open-market purchases, 2 sales worth $240K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Sales
Other filings
About Biogen Inc.
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while…
Drug Manufacturers - General
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works